MindMed

MindMed is a clinical-stage biopharmaceutical company founded in 2019 with a mission to address brain health disorders, focusing on psychiatry, addiction, pain, and neurology. The company aims to be a global leader in developing and delivering treatments to improve patient outcomes. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. The company has received a significant $175.00M Post-IPO Equity investment on 07 March 2024 from a consortium of investors including Marshall Wace, Ally Bridge Group, Commodore Capital, Deep Track Capital, Driehaus Capital Management, Janus Handerson, Octagon Capital Advisors, Soleus Capital, Woodline Partners, and Great Point Partners. MindMed's focus on innovative drug candidates targeting the serotonin, dopamine, and acetylcholine systems places it at the forefront of biotechnology, healthcare, and pharmaceutical industries, showcasing its potential to address unmet medical needs and drive advancements in brain health treatments.